Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Serum B-type natriuretic peptide does not increase with higher systolic blood pressure in obese men despite evidence of blood pressure-related increases in left ventricular mass and filling pressure

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effect of insulin on natriuretic peptide gene expression in porcine heart

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists

    Research output: Contribution to journalReviewpeer-review

  3. GIP and the gut-bone axis - physiological, pathophysiological and potential therapeutic implications

    Research output: Contribution to journalReviewpeer-review

  1. Symptoms and biomarkers associated with undiagnosed celiac seropositivity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Biomarkers and Their Relation to Cardiac Function Late After Peripartum Cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

B-type natriuretic peptide (BNP) is a cardiac hormone secreted predominantly from the ventricles in response to increased ventricular pressure. Along this line, hypertensive patients with left ventricular hypertrophy typically have high circulating BNP concentrations. BNP has natriuretic and vasodilatory actions. Obese persons have low circulating BNP concentrations, and a relative lack of this natriuretic and vasodilatory factor could contribute to obesity-related hypertension. The relationship between BNP, BP, left ventricular mass (LVM), and left ventricular filling pressure among obese persons is not clear. To address this issue, we studied 98 healthy obese medication-free men with normal left ventricular ejection fraction. We measured BP using 24 -h ambulatory (A) BP recordings, LVM and E/e', an estimate of left ventricular filling pressure, using echocardiography, and fasting BNP in serum. Mean systolic ABP ± SD was 114 ± 4 mm Hg in 1st and 149 ± 8 mm Hg in 4th systolic ABP quartile, P < 0.001. LVM and E/e' increased across systolic ABP quartiles (mean LVM±SD: 81.5±13.7 g/m2 in 1st and 100.1 ± 26.7 g/m2 in 4th quartile, P = 0.018; mean E/e'±SD: 5.3±1.6 in 1st and 7.0 ± 2.0 in 4th quartile, P = 0.002). In contrast, serum BNP did not increase across systolic ABP quartiles (median (IQR): 6.7 (3.1-12.3) pg/ml in 1st and 5.3 (2.8-9.7) pg/ml in 4th quartile, P = 0.75). Unexpectedly, among healthy obese medication-free men, serum BNP does not increase with higher systolic ABP despite evidence of BP-related increases in LVM and E/e'. This further suggests that a relatively low amount of circulating BNP could contribute to obesity-related hypertension in its early stages.

Original languageEnglish
JournalPeptides
Volume134
Pages (from-to)170390
ISSN0196-9781
DOIs
Publication statusPublished - Dec 2020

Bibliographical note

Copyright © 2020 Elsevier Inc. All rights reserved.

    Research areas

  • B-type natriuretic peptide, Blood pressure, E/e', Left ventricular hypertrophy, Left ventricular mass, Obesity

ID: 60791876